Literature DB >> 24252723

HPLC method development, validation and impurity characterization for an antitumor Hsp90 inhibitor-PU-H71 (NSC 750424).

Mingtao Liu1, Jennie Wang2, Xiaogang Wu1, Euphemia Wang1, Diego Baptista1, Brendan Scott3, Paul Liu4.   

Abstract

An HPLC method for the assay of the heat shock protein 90 inhibitor, PU-H71 (NSC 750424), has been developed and validated. The stress testing of PU-H71 was carried out in accordance with ICH guidelines Q1A (R2) under aqueous, acidic, alkaline, oxidative, thermolytic and photolytic conditions. The separation of PU-H71 from its impurities and degradation products was achieved within 50min on a Mac-Mod ACE 3 C18 column (150mm×4.6mm i.d., 3μm) with a gradient mobile phase comprising 20-95% acetonitrile in water, with 0.1% trifluroacetic acid in both phases. LC-quadrupole TOF/MS was used to obtain accurate mass data on various components as well as on their fragments for characterization of impurities and degradation products. The proposed HPLC assay method was validated for specificity, linearity (concentration range 0.1-0.3mg/mL, r≥0.9998), accuracy (recovery 99.7-101.1%), precision (intra-lab RSD≤1.39%, inter-lab RSD≤0.91%), sensitivity (LOD 0.08μg/mL), and ruggedness. The developed method was suitable for the assay and stability monitoring of PU-H71 drug substance.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ACN; ADP; ATP; Forced degradation; HPLC validation; Hsp; Impurity characterization; NSC 750424; PDA; PU-H71; Q-TOF; RRT; S/N; Stability study; TFA; acetonitrile; adenosine diphosphate; adenosine triphosphate; heat shock protein; photodiode array; quadrupole time-of-flight; relative retention time; signal to noise ratio; trifluoroacetic acid

Mesh:

Substances:

Year:  2013        PMID: 24252723      PMCID: PMC3954645          DOI: 10.1016/j.jpba.2013.10.021

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  15 in total

Review 1.  GHKL, an emergent ATPase/kinase superfamily.

Authors:  R Dutta; M Inouye
Journal:  Trends Biochem Sci       Date:  2000-01       Impact factor: 13.807

Review 2.  Structure and functional relationships of Hsp90.

Authors:  Chrisostomos Prodromou; Laurence H Pearl
Journal:  Curr Cancer Drug Targets       Date:  2003-10       Impact factor: 3.428

Review 3.  ATPases as drug targets: learning from their structure.

Authors:  Patrick Chène
Journal:  Nat Rev Drug Discov       Date:  2002-09       Impact factor: 84.694

Review 4.  Structure and mechanism of the Hsp90 molecular chaperone machinery.

Authors:  Laurence H Pearl; Chrisostomos Prodromou
Journal:  Annu Rev Biochem       Date:  2006       Impact factor: 23.643

5.  Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.

Authors:  Huazhong He; Danuta Zatorska; Joungnam Kim; Julia Aguirre; Laura Llauger; Yuhong She; Nian Wu; Robert M Immormino; Daniel T Gewirth; Gabriela Chiosis
Journal:  J Med Chem       Date:  2006-01-12       Impact factor: 7.446

Review 6.  Constantly updated knowledge of Hsp90.

Authors:  Kazuya Terasawa; Michiko Minami; Yasufumi Minami
Journal:  J Biochem       Date:  2005-04       Impact factor: 3.387

7.  The middle domain of Hsp90 acts as a discriminator between different types of client proteins.

Authors:  Patricija Hawle; Martin Siepmann; Anja Harst; Marco Siderius; H Peter Reusch; Wolfgang M J Obermann
Journal:  Mol Cell Biol       Date:  2006-09-18       Impact factor: 4.272

Review 8.  New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.

Authors:  Yanyan Li; Tao Zhang; Steven J Schwartz; Duxin Sun
Journal:  Drug Resist Updat       Date:  2009 Feb-Apr       Impact factor: 18.500

Review 9.  The Hsp90 chaperone complex as a novel target for cancer therapy.

Authors:  M P Goetz; D O Toft; M M Ames; C Erlichman
Journal:  Ann Oncol       Date:  2003-08       Impact factor: 32.976

10.  Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer.

Authors:  Anna Rodina; Maria Vilenchik; Kamalika Moulick; Julia Aguirre; Joungnam Kim; Anne Chiang; Julie Litz; Cristina C Clement; Yanlong Kang; Yuhong She; Nian Wu; Sara Felts; Peter Wipf; Joan Massague; Xuejun Jiang; Jeffrey L Brodsky; Geoffrey W Krystal; Gabriela Chiosis
Journal:  Nat Chem Biol       Date:  2007-07-01       Impact factor: 15.040

View more
  2 in total

Review 1.  The essential roles of chemistry in high-throughput screening triage.

Authors:  Jayme L Dahlin; Michael A Walters
Journal:  Future Med Chem       Date:  2014-07       Impact factor: 3.808

2.  A sensitive multidimensional method for the detection, characterization, and quantification of trace free drug species in antibody-drug conjugate samples using mass spectral detection.

Authors:  Robert E Birdsall; Sean M McCarthy; Marie Claire Janin-Bussat; Michel Perez; Jean-François Haeuw; Weibin Chen; Alain Beck
Journal:  MAbs       Date:  2015-12-14       Impact factor: 5.857

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.